How an experimental drug reverses fatty liver disease : comp

A drug in clinical trials as a treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) works with a one-two punch that shuts down triglyc

Related Keywords

Dallas , Texas , United States , Paulj Thomas , Arun Radhakrishnan , Simeng Wang , Michael Brown , C Vincent Prothro , Jonathan Cohen , Wa Monty Moncrief , Shunxing Rong , Helen Hobbs , Philip Obryan Montgomery , Ajay Horton , Scott Grundy , Louisa Beecherl Jr , Joseph Goldstein , Jeffrey Mcdonald , Shili Li , Nutrition Obesity Research Center , Arteriosclerosis Research , Cardiology Research , Ut Southwestern Medical Center , Leducq Foundation , National Institutes Of Health , Research Scientist , Biomedical Research , Division Of Digestive , Welch Foundation , Human Nutrition Research , Medical Center , Cell Metabolism , Internal Medicine , Liver Diseases , Human Nutrition , National Institutes , Drug Administration Approved , Dallas Heart Study , Goncalo Dias , Chai Wan Kim , Assistant Professors , Molecular Genetics , Clinical Fellow , Regental Professor , Moncrief Distinguished Chair , Prothro Distinguished Chair , Distinguished Chair , Philipo Bryan Montgomery , Developmental Biology , Eugene Mcdermott Distinguished Chair , Human Growth , Heart Ball Chair , Distinguished University Chair , Human Nutrition Director , Endowed Chair , Scott Grundy Director ,